Historical Valuation
Health Catalyst Inc (HCAT) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.54 is considered Undervalued compared with the five-year average of -26.11. The fair price of Health Catalyst Inc (HCAT) is between 4.89 to 27.91 according to relative valuation methord. Compared to the current price of 2.47 USD , Health Catalyst Inc is Undervalued By 49.49%.
Relative Value
Fair Zone
4.89-27.91
Current Price：2.47
49.49%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Health Catalyst Inc (HCAT) has a current Price-to-Book (P/B) ratio of 0.49. Compared to its 3-year average P/B ratio of 1.19 , the current P/B ratio is approximately -59.11% higher. Relative to its 5-year average P/B ratio of 2.56, the current P/B ratio is about -81.08% higher. Health Catalyst Inc (HCAT) has a Forward Free Cash Flow (FCF) yield of approximately -8.57%. Compared to its 3-year average FCF yield of -3.82%, the current FCF yield is approximately 124.20% lower. Relative to its 5-year average FCF yield of -3.33% , the current FCF yield is about 157.14% lower.
P/B
Median3y
1.19
Median5y
2.56
FCF Yield
Median3y
-3.82
Median5y
-3.33
Competitors Valuation Multiple
AI Analysis for HCAT
The average P/S ratio for HCAT competitors is 3.92, providing a benchmark for relative valuation. Health Catalyst Inc Corp (HCAT.O) exhibits a P/S ratio of 0.54, which is -86.26% above the industry average. Given its robust revenue growth of -0.04%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for HCAT
1Y
3Y
5Y
Market capitalization of HCAT increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of HCAT in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is HCAT currently overvalued or undervalued?
Health Catalyst Inc (HCAT) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.54 is considered Undervalued compared with the five-year average of -26.11. The fair price of Health Catalyst Inc (HCAT) is between 4.89 to 27.91 according to relative valuation methord. Compared to the current price of 2.47 USD , Health Catalyst Inc is Undervalued By 49.49% .
What is Health Catalyst Inc (HCAT) fair value?
HCAT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Health Catalyst Inc (HCAT) is between 4.89 to 27.91 according to relative valuation methord.
How does HCAT's valuation metrics compare to the industry average?
The average P/S ratio for HCAT's competitors is 3.92, providing a benchmark for relative valuation. Health Catalyst Inc Corp (HCAT) exhibits a P/S ratio of 0.54, which is -86.26% above the industry average. Given its robust revenue growth of -0.04%, this premium appears unsustainable.
What is the current P/B ratio for Health Catalyst Inc (HCAT) as of Jan 10 2026?
As of Jan 10 2026, Health Catalyst Inc (HCAT) has a P/B ratio of 0.49. This indicates that the market values HCAT at 0.49 times its book value.
What is the current FCF Yield for Health Catalyst Inc (HCAT) as of Jan 10 2026?
As of Jan 10 2026, Health Catalyst Inc (HCAT) has a FCF Yield of -8.57%. This means that for every dollar of Health Catalyst Inc’s market capitalization, the company generates -8.57 cents in free cash flow.
What is the current Forward P/E ratio for Health Catalyst Inc (HCAT) as of Jan 10 2026?
As of Jan 10 2026, Health Catalyst Inc (HCAT) has a Forward P/E ratio of 6.35. This means the market is willing to pay $6.35 for every dollar of Health Catalyst Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Health Catalyst Inc (HCAT) as of Jan 10 2026?
As of Jan 10 2026, Health Catalyst Inc (HCAT) has a Forward P/S ratio of 0.54. This means the market is valuing HCAT at $0.54 for every dollar of expected revenue over the next 12 months.